Studies guselkumab in psoriatic arthritis patients who also have fatty liver disease
Tests guselkumab in people with psoriatic arthritis and fatty liver disease.
Plain-language title generated from the registry record
Registry title: Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
Key facts
- Where
- San Diego, United StatesSee the site
Where in United States
- University of California San DiegoSan Diego, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Diego
- Trial code
- NCT06586281
- Record updated
- 10 June 2026
- Original description
While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.Read full original descriptionShow less
Elucidating Shared Mechanisms Contributing to Non-Alcoholic Fatty Liver Disease (NAFLD) and Psoriatic Arthritis (PsA) Disease Severity With Guselkumab Therapy
While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.
Inclusion: Adults with diagnosis of PsA fulfilling the classification for PsA (CASPAR) criteria; Must have:; 1 or more swollen joint(s) and/or one or more active sites of enthesitis; AND/OR; 1 or more psoriatic plaques; No changes in the regular medication regimen within the last three months, and no use of systemic and/or chronic steroids within 8 weeks leading up to the study; Overweight or obese by BMI ≥ 25.0 kg/m2 or ≥ 23.0 for Asian participants; Patients are starting Guselkumab therapy for PsA as indicated by primary rheumatologist; Elevated liver fat on controlled attenuation parameter (CAP) ≥ 288 dB/m, which is consistent with NAFLD after exclusion of secondary causes of liver disease.
Exclusion: Patients with prior exposure to IL12/23i, IL-17i, JAKi, or TYK2i. Patients with exposure to more than 2 TNFi; History of known HIV infection; Evidence of other causes of chronic liver disease; Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg); Previous or current infection with Hepatitis C as defined by presence of hepatitis C virus Abin serum (anti-HCV Ab); Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy; Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis; Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease; Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency; Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y/H63D; Drug-induced liver disease as defined on the basis of typical exposure and history; Bile duct obstruction as shown by imaging studies; History of gastrointestinal bypass surgery or ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, amiodarone or tetracycline in the previous 6 months; Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices; Presence of regular and/or excessive use of alcohol (defined as >30g/day for males and >15g/day for females) for a period longer than 2 years at any times in the last 10 years; Serum creatinine > 2.0 mg/dL; The subject is a pregnant or nursing female or is planning to become pregnant; Life expectancy less than 5 years.